Navigation Links
Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
Date:5/30/2013

SOUTH SAN FRANCISCO, CA May 30, 2013 Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection. It is the only known nucleoside analog currently in clinical development for the treatment of RSV. ALS-8176 demonstrates potent anti-viral activity across multiple strains of RSV in preclinical studies and represents an important step forward in the development of more effective treatments for this serious and often life threatening disease.

The randomized, double-blind, placebo-controlled, Phase 1 study of orally administered ALS-8176 will evaluate safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses in healthy volunteers. The trial will assess several dose levels in up to 90 healthy adults.

ALS-8176 was discovered following the optimization of screening hits obtained through testing the Alios proprietary nucleoside analog library against replicating RSV in cell culture. The compound acts by blocking replication through a classic chain-termination mechanism and inhibits all RSV strains tested.

Due to their high barrier to viral resistance, nucleoside analogs have become the backbone of antiviral therapy in many clinical settings including the treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and herpes simplex virus (HSV). More recently, emerging data suggest the pivotal role nucleoside analogs will play in the future treatment of chronic hepatitis C (HCV).

"Alios believes ALS-8176 has great potential to become an effective first-line antiviral therapy for RSV infection, a disease where few treatment options currently exist," said Lawrence M. Blatt, PhD, Chief Executive Officer. "The advancement of ALS-8176 for RSV, together with the recently reported positive clinical data with VX-135 (formerly ALS-2200, an anti-HCV nucleotide analog), demonstrates the broad capabilities of the Alios discovery platform. We are currently utilizing this platform to screen against several infectious diseases with high unmet medical needs."

Alios has built its drug discovery engine based on its core competencies in nucleoside synthetic chemistry, including prodrug chemistry, and a breadth and depth of virology expertise built over decades in the antiviral field. The Alios platform has been utilized to create a portfolio of antiviral drug candidates against multiple viruses including HCV, RSV, picornavirus (rhinovirus), and norovirus. In addition, the company is selectively pursuing non-nucleoside drug discovery in areas where combination regimens may be particularly useful.


'/>"/>

Contact: John Donovan
press@aliosbiopharma.com
650-635-5504
Alios BioPharma, Inc.
Source:Eurekalert

Related biology news :

1. Exclusive agreement to distribute Affinity Biosensors Archimedes system extends Malvern Instruments biopharma solutions
2. Discovery of a molecule that initiates maturation of mammalian eggs can lead to more IVF pregnancies
3. Carnegie Mellon neuroscientists discover new phase of synaptic development
4. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
5. FDA approves Phase II of stem cell trial for ALS led by U-Ms Dr. Eva Feldman
6. In beef production, cow-calf phase contributes most greenhouse gases
7. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
8. National Geographic unveils new phase of genographic project
9. King Richard III search in new phase after discovery has potential to rewrite history
10. Center for Clinical and Translational Science awards new pilot grants
11. Elseviers Maturitas publishes clinical guide on endometrial assessment in postmenopausal women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology: